Open Nav

Saturn Biosciences

Fundraising and partnering

  • Date:Thursday, October 18
  • Time:2:45 PM - 3:00 PM
  • Room:Elizabethan C
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Saturn Biosciences is developing SAT012, a fusion of functional IL12 with a targeting antibody against highly selective tumor antigen ED-B. Interleukin 12 (IL12) is the key anti-tumor cytokine acting by induction of T and NK cells to attack the tumor. IL12 is also the key cytokine to turn "exhausted" CD8+T-cells back on after their exposure to anti-PD1 Abs. "Naked" IL12 has shown good responses as a single agent but with serious side effects. The key advantages of SAT012 over the other developments are its targeted localization of IL12 to tumors to avoid systemic exposure (side-effects) and its much longer half-life than the naked IL12. SAT012 has completed a successful Phase 1 as a monotherapy which established a suitable dose and an efficacy signal that has proven to be superior to other efforts with cytokines. SAT012 is being readied for a Phase 1b/2 in solid tumors in combination with anti-PD1/PDL1 mAbs to increase the hitherto low numbers of responders to anti-PD1/PDL mAbs.
  • Company
  • Company HQ City:Cambridge
  • Company HQ Country:United Kingdom
  • CEO/Top Company Official:Raymond Spencer
  • Year Founded:2015
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :BC1-IL12 (SAT012)
  • Development Phase of Primary Product:Phase II
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :1
  • Previous and Current Investors:Founders
  • Total Amount Raised to Date, In All Rounds:100000